Stock comparison
Genmab A/S
Haleon
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
HLN
Haleon
Market cap
$41.25B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | HLN | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 54D | GMAB |
| Benjamin Graham | 64C | 55C | GMAB |
| Philip Fisher | 48D | 49D | HLN |
| Peter Lynch | 25F | 54C | HLN |
| Joel Greenblatt | 76B | 49D | GMAB |
| Charlie Munger | 68C | 47D | GMAB |
| Terry Smith | 71C | 43D | GMAB |
Side-by-side metrics
| Metric | GMAB | HLN |
|---|---|---|
| Market cap | $16.5B | $41.25B |
| P/E (TTM) | 6.2x | 28.8x |
| EV/EBIT | 12.0x | 35.6x |
| ROIC (TTM) | 43.78% | 4.13% |
| Gross margin | 93.88% | 61.45% |
| Net margin | 18.23% | 12.59% |
| Revenue CAGR 5y | -18.45% | 3.11% |
| EPS CAGR 5y | -23.48% | 4.66% |
| Debt / Equity | 0.1x | 0.5x |
| Dividend yield | 0.0% | 2.15% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- ROIC (TTM)43.78%vs 4.13%+91%
- Debt / Equity0.1xvs 0.5x+86%
- P/E (TTM)6.2xvs 28.8x+79%
- EV/EBIT12.0xvs 35.6x+66%
HLN leads on
- EPS CAGR 5y4.66%vs -23.48%+120%
- Revenue CAGR 5y3.11%vs -18.45%+117%
- Dividend yield2.15%vs 0.0%+100%
- Market cap$41.25Bvs $16.5B+60%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.